Intrinsiqq
Protara Therapeutics Inc. logo

Protara Therapeutics Inc. Quality Score

TARA

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-1.6x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-1.9x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Capital Structure
100/100
-$125M

Net cash position, no leverage concern

2014
$84.0M
$0.00
TTM
$127M
$2.00M
CashDebt
Return on Capital
0/100
-38.9%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Protara Therapeutics (TARA) quality: score, margins and returns

Protara Therapeutics (TARA) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100 and -38.9% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Protara Therapeutics (TARA) a high-quality business?+

Protara Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -38.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Protara Therapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from TARA's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Protara Therapeutics scores well and where it falls behind.

What is Protara Therapeutics's return on invested capital (ROIC)?+

Protara Therapeutics earns about -38.9% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to TARA's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 3 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TARA

CompareIntrinsic value
HUMAHumacyte, Inc.
$0.45-17.97%0
DBVTDBV Technologies S.A.
$9.01-4.35%10
ALGSAligos Therapeutics Inc.
$1.22-2.40%10
DYAIDyadic International Inc.
$0.29-6.45%25
ATRAAtara Biotherapeutics, Inc.
$6.33-0.16%25
CRISCuris Inc.
$0.44-7.21%35
OTLKOutlook Therapeutics Inc.
$0.39-3.32%10
SABSSab Biotherapeutics Inc.
$2.81-3.44%19

Held by ETFs

TARA is in 3 US ETFs. The largest of them, with TARA's weight in each:

Spot a number that looks wrong? Check it in TARA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing TARA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.